NasdaqGS:CBAY

Stock Analysis Report

Executive Summary

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has CymaBay Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.7%

CBAY

0.06%

US Pharmaceuticals

0.5%

US Market


1 Year Return

-53.7%

CBAY

-7.8%

US Pharmaceuticals

6.8%

US Market

Return vs Industry: CBAY underperformed the US Pharmaceuticals industry which returned -7.8% over the past year.

Return vs Market: CBAY underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

CBAYIndustryMarket
7 Day7.7%0.06%0.5%
30 Day-15.6%-1.7%-0.8%
90 Day-25.8%-1.3%-0.9%
1 Year-53.7%-53.7%-5.5%-7.8%9.2%6.8%
3 Year163.9%163.9%18.4%10.1%45.6%36.2%
5 Year-36.0%-36.0%22.2%9.3%63.2%45.4%

Price Volatility Vs. Market

How volatile is CymaBay Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CymaBay Therapeutics undervalued compared to its fair value and its price relative to the market?

1.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CBAY is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: CBAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBAY is good value based on its PB Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is CymaBay Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

35.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CBAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CBAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CBAY is forecast to have no revenue next year.

High Growth Revenue: CBAY is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CBAY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CymaBay Therapeutics performed over the past 5 years?

-64.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CBAY is unprofitable, and losses have increased over the past 5 years at a rate of -64.2% per year.

Accelerating Growth: Unable to compare CBAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: CBAY has a negative Return on Equity (-36.06%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CBAY is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CBAY is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is CymaBay Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CBAY's short term assets ($249.8M) exceeds its short term liabilities ($15.4M)

Long Term Liabilities: CBAY's short term assets (249.8M) exceeds its long term liabilities (2.0M)


Debt to Equity History and Analysis

Debt Level: CBAY is debt free.

Reducing Debt: CBAY has no debt compared to 5 years ago when its debt to equity ratio was 52.9%.

Debt Coverage: CBAY has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CBAY has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CBAY has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CBAY's debt is covered by short term assets.


Next Steps

Dividend

What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CBAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CBAY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CBAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CymaBay Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Sujal Shah (46yo)

2.6yrs

Tenure

US$1,938,017

Compensation

Mr. Sujal A. Shah has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah served as an Interim Chief Executive Officer and Interim President of Cym ...


CEO Compensation Analysis

Compensation vs. Market: Sujal's total compensation ($USD1.94M) is about average for companies of similar size in the US market ($USD1.80M).

Compensation vs Earnings: Sujal's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.5yrs

Average Tenure

56.5yo

Average Age

Experienced Management: CBAY's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

52yo

Average Age

Experienced Board: CBAY's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: CBAY insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$21,50015 Oct 19
Sujal Shah
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$4.30
BuyUS$27,65524 Sep 19
Sujal Shah
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$5.55
BuyUS$65,39921 Dec 18
Sujal Shah
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$6.54
SellUS$1,123,58819 Dec 18
Abingworth LLP
EntityCompany
Shares142,381
Max PriceUS$8.17

Ownership Breakdown


Management Team

  • Klara Dickinson-Eason (51yo)

    Chief Regulatory & Compliance Officer

    • Tenure: 0.8yrs
  • Paul Quinlan (56yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.8yrs
    • Compensation: US$2.96m
  • Patrick O'Mara (58yo)

    Senior Vice President of Business Development

    • Tenure: 2.8yrs
  • Charles McWherter (64yo)

    Senior VP & Chief Scientific Officer

    • Tenure: 6.8yrs
    • Compensation: US$1.79m
  • Rob Martin (57yo)

    Senior Vice President of Manufacturing & Nonclinical Development

    • Tenure: 4.5yrs
  • Sujal Shah (46yo)

    President

    • Tenure: 2.6yrs
    • Compensation: US$1.94m
  • Ken Boehm

    Vice President of Human Resources

    • Tenure: 0.5yrs
  • Rob Wills (65yo)

    Independent Chairman

    • Tenure: 4yrs
    • Compensation: US$183.53k
  • Janet Dorling

    Chief Commercial Officer

    • Tenure: 0.2yrs
  • Dan Menold (49yo)

    Vice President of Finance

    • Tenure: 2.5yrs
    • Compensation: US$857.26k

Board Members

  • Carl Goldfischer (60yo)

    Independent Director

    • Tenure: 16.2yrs
    • Compensation: US$181.03k
  • Paul Truex (50yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$171.53k
  • Kurt von Emster (52yo)

    Independent Director

    • Tenure: 10.5yrs
    • Compensation: US$175.28k
  • Jerrold Olefsky

    Member of Clinical Advisory Board and Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mayer Davidson

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Morris Birnbaum

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steve Shoelson

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Robert Gelfand

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Sujal Shah (46yo)

    President

    • Tenure: 2.6yrs
    • Compensation: US$1.94m
  • Rob Wills (65yo)

    Independent Chairman

    • Tenure: 4yrs
    • Compensation: US$183.53k

Company Information

CymaBay Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CymaBay Therapeutics, Inc.
  • Ticker: CBAY
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$326.330m
  • Shares outstanding: 68.70m
  • Website: https://www.cymabay.com

Number of Employees


Location

  • CymaBay Therapeutics, Inc.
  • 7575 Gateway Boulevard
  • Suite 110
  • Newark
  • California
  • 94560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBAYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2014
C0IDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014
0I5PLSE (London Stock Exchange)YesCommon StockGBUSDJan 2014

Biography

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:44
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.